한국인 다낭성난소증후군 여성에서 Metformin과 Rosiglitazone의 치료효과 = Therapeutic Effects of Metformin and Rosiglitazone in Korean Women with Polycystic Ovary Syndrome

국문 초록 (Abstract)

연구배경: 인슐린저항성은 다낭성난소증후군(polycystic ovary syndrome, PCOS)의 주된 병인이며, 고인슐린혈증이 월경장애나 불임, 고안드로겐혈증에 기여하는 것으로 알려져 있다. 최근 PCOS에서 메트포민이나 글리타존과 같은 인슐린감수성개선제의 사용이 효과적인 것으로 보고되고 있다. 본 연구에서는 PCOS에서 인슐린감수성개선제 투여 후 대사적, 내분비적 이상의 개선 여부와, 인슐린감수성개선제 효과의 예측인자를 알아보고자 하였다.
방법: 총 62명의 PCOS 여성을 대상으로 하여 기초검사인 체질량지수, 75 그람 경구당부하검사, 혈청지질, 성호르몬을 측정하고, 정상혈당 클램프 검사를 시행하였다. 메트포민 1.5g/day 혹은 로지글리타존 4mg/day를 투여한 후 8~12주 후에 클램프검사를 재시행하였다. 약물투여 후 적어도 3개월 동안 지속적인 질출혈이 있는 경우에 월경이 회복된 것으로 정하였다.
결과: 36명이 월경이 회복되었고 5명이 임신이 되어 약물반응도는 66.7%였다. 약물 반응군과 무반응군 사이의 유의한 대사적 지표나 성호르몬의 차이는 없었다. PCOS 여성에서 약물치료 후 인슐린감수성은 유의하게 증가하고(4.7 ±0.2 vs 5.5±0.4mg/kg/min, P<0.05), 유리 테스테스테론 농도는 유의하게 감소되었으나(72.5±39.9 vs 45.8± 3.8pmol/L, P<0.05), 체중의 유의한 변화는 없었다.
결론: 한국인 PCOS 여성에서 적어도 12주 이상 인슐린감수성개선제를 사용하는 것은 월경의 회복 및 고안드로겐혈증의 개선에 효과적이었다. 하지만 약물 반응을 예측할 수 있는 대사 지표나 성호르몬의 특징은 관찰할 수 없었다.

다국어 초록 (Multilingual Abstract)

Background: Insulin resistance is a central feature of polycystic ovary syndrome (PCOS), and hyperinsulinemia contributes to anovulation, oligo or amenorrhea, hyperandrogenism and infertility in women with PCOS. The use of insulin sensitizers, such as metformin or thiazolidinedione, in PCOS is becoming increasingly accepted. The purpose of our study was to evaluate the therapeutic effects of metformin and rosiglitazone on the metabolic and reproductive derangement, and find parameters predicting their therapeutic efficacy in Korean PCOS women. Methods: Sixty-two women with PCOS were recruited. The baseline characteristics, including BMI, glucose tolerance test, lipid profiles, sex hormones and hyperinsulinemic euglycemic clamp test, were assessed. After the administration of the insulin sensitizer (metformin 1.5g/day or rosiglitazone 4mg/day) for 3 months, the insulin sensitivity was reassessed. A drug response was defined as menstrual restoration or pregnancy. Results: Of the 62 women with PCOS, 36 gained restored regular menstruation, and a further 5 conceived (a drug response rate of 66.7%). There were no significant clinical differences between responders and nonresponders. Twelve weeks after taking the drugs, the insulin sensitivity was significantly improved (M-value 4.7±0.2 vs. 5.5±0.4mg/kg/min, P<0.05), and the free testosterone levels(72.5±39.9 vs. 45.8 ±3.8pmol/L, P<0.05) were significantly decreased, without significant weight reduction. Conclusion: Metformin and rosiglitazone restored menstruation in 66.1% of women with PCOS. Hyperandrogenemia and insulin sensitivity were significantly improved with the use of the two drugs. However, metabolic or hormonal markers for predicting the drug response could not be found

참고문헌 (Reference)

1 "한국인 여성에서 다낭성난소증후군 유병률 및 진단기준" 20 : 146-, 2005

2 "처음 진단받은 다낭성난소증후군 환자의 임상적 특징" 20 : 147-, 2005

3 "서울지역 여자대학생에서 다낭성난소증후군의 유병률" 20 : 120-126, 2005

4 "Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase" 276 : 16767-16771, 2001

5 "The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome" 81 : 3299-3306, 1996

6 "The blooming of the French lilac" 108 : 1105-1107, 2001

7 "The biological variation of testosterone and sex hormone-binding globulin implications for SHBG as a surrogate marker of insulin resistance" 1528-1533, 2003

8 "Sensitization to insulin in adolescent girls to normalize hirsutism and hyperinsulinism after precocious pubarche" 85 : 3526-3530, 2000

9 "Role of insulin resistance in human disease" 37 : 1595-1607, 1988

10 "Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome and its clinical implications" 15 : 111-122, 1997

11 "Role of AMP-activated protein kinase in mechanism of metformin action" 108 : 1167-1174, 2001

12 "Revised 2003 consensus on diagnostic criteria and long health risks related to polycystic ovary syndrome" 19 : 41-47, 2004

13 "Profound peripheral insulin resistance,independent of obesity,in the polycystic ovary syndrome" 38 : 1165-1174, 1989

14 "Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States:a prospective study" 83 : 3078-3082, 1998

15 "Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin" 18 : 1618-1625, 2003

16 "PCOS/Troglitazone study Group Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome" 79 : 927-937, 2003

17 "Obesity and the PCO syndrome" 26 : 883-896, 2002

18 "Metformin-induced resumption of normal menses in 39 of 43(91%)previously amenorrheic women with the polycystic ovary syndrome" 48 : 511-519, 1999

19 "Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance." 109 : S259-S264, 2001

20 "Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia" and systolic blood pressure 647-43 654, 1994

21 "Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome" 69 : 691-696, 1998

22 "Metformin increases the ovulatory rate and pregnancy rate from clomiphen cirate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone" 75 : 310-315, 2001

23 "Metformin directly inhibits androgen production in human theca cells" 76 : 517-524, 2001

24 "Insulin sensitivity in women with polycystic ovary syndrome relationship to hyperandrogenemia" 605-612, 1994

25 "Insulin lowering drugs in polycystic ovary syndrome" 28 : 153-164, 2001

26 "Insulin action in the polycystic ovary syndrome" 28 : 341-359, 1999

27 "Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone" 76 : 1057-1059, 2001

28 "Glucose clamp technique:a method for quantifying insulin secretion and resistance" 237 : 1979

29 "Effects of metformin on spontaneous and clomiphene- induced ovulation in the polycystic ovary syndrome" 338 : 1876--1880, 1998

30 "Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome" 72 : 282-285, 1999

31 "Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome" 49 : 361-367, 2004

32 "Effects of metformin and rosiglitazone,alone and in combination,in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity" 82 : 893-902, 2004

33 "Effect of the insulin sensitizer pioglitazone on insulin resistance,hyperandrogenism,and ovulatory dysfuction in women with polycystic ovary syndrome" 89 : 3835-3840, 2004

34 "Effect of rosiglitazone on spontaneous and clomiphen citrate-induced ovulation in women with polycystic ovary syndrome" 79 : 562-566, 2003

35 "Effect of rosiglitazone on insulin resistance,growth factors,and reproductive disturbances in women with polycystic ovary syndrome" 81 : 624-629, 2004

36 "Effect of rosiglitazone on insulin resistance and hyperandrogenism in polyc ystic ovary syndrome." 37 : 271-273,

37 "Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome" 19 : 534-539, 2004

38 "Definition ,diagnosis and classification of diabetes mellitus and its complication Report of a WHO consultation Diagnosis and classification of diabetes mellitus" World Health Organization 1999

39 "Association of bioavailable and total testosterone with insulin resistance influence of sex hormone-binding globulin and body fat" 27 : 861-868, 2004